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Toxoplasma infection in pregnant women may cause congenital toxoplasmosis.
Diagnosis of infection is based on serological tests aimed at detecting IgM and IgG
antibodies against Toxoplasma gondii. However, IgM antibodies are not an accurate
marker for discriminating between acute and latent infection. Detection of residual
or persistent IgM may occur months or even years after primary infection, while the
IgG avidity test is a rapid means of identifying latent infections in pregnant women
who exhibit both IgG and IgM anti-Toxoplasma antibodies on initial testing during
pregnancy. In this study, we assessed and compared the performances of four
commercially available Toxoplasma IgG avidity tests in immunocompetent and
immunocompromised patients with acute and latent toxoplasmosis. The positive
predictive value of high avidity to confirm latent toxoplasmosis was 100% for all the
assays, indicating that high avidity is a hallmark of latent infection. However, the
negative predictive value of high avidity ranged from 99.2% (bioMérieux) to 95.3%
(Abbott), indicating that acute toxoplasmosis could not be reliably diagnosed based
on low IgG avidity alone. Thus, the avidity test provides a rapid means for identifying
latent Toxoplasma infection in immunocompetent pregnant women presenting both
IgG and IgM anti-Toxoplasma antibodies on initial testing. In terms of cost-
effectiveness, avidity testing is a powerful tool that optimizes screening and follow-
up of pregnant women while minimizing the costs of screening by avoiding
subsequent costly maternal and fetal investigation and unnecessary treatment. The
cheapest assay, Vidas Toxo IgG Avidity, also had the best performance for the
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